Compare Moderna, Inc. (MRNA) vs iShares Silver Trust (SLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs iShares Silver Trust — how do they compare? Moderna, Inc. trades at $225 (market cap $78.65B), while iShares Silver Trust trades at $54.78 (market cap $29.02B). The key difference: Moderna, Inc. is far larger — about 2.7× iShares Silver Trust's market cap, and Moderna, Inc. is trading nearer its 52-week high, iShares Silver Trust nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Moderna, Inc. for 59 Days and iShares Silver Trust for 89 Days on average.
| MRNA | SLV | |
|---|---|---|
Market Cap | $78.65B | $29.02B |
Volume | 37,373,437 | 16,510,334 |
Sector | Health | — |
52-Week High | $225.00 | $105.57 |
52-Week Low | $22.36 | $42.40 |
Typical Hold Time | 59 Days | 89 Days |
Enterprise Value | $74.80B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $197.00, up 0.26% today, reflecting a strong 2026 rally. The stock is technically bullish, with moving averages signaling strength and key support at $194. Fundamentally, revenue has declined from pandemic peaks to $1.92 billion in 2025, with net losses widening to -$2.82 billion, though recent quarters have beaten EPS estimates. The company's inclusion in the Nasdaq-100 index effective October 9, 2026, adds a positive catalyst. Analyst sentiment is mixed, with a consensus price target of $115.70 but a high target of $245.00, indicating divergent views on valuation after the stock's significant run-up.
The outlook for Moderna hinges on its pipeline beyond COVID-19, particularly cancer vaccines, but high valuation ratios (P/S of 35.08) and persistent losses pose risks. Upside potential exists if new products gain traction, yet investors face volatility from clinical trial outcomes and competitive pressures. The stock's proximity to 52-week highs suggests caution amid profit-taking signals from some analysts.
SLV (iShares Silver Trust) trades at $53.45, down 0.69% with a bearish technical signal. The ETF shows minimal operational activity with $0 revenue but generated $2.17M net income in 2024. Assets surged to $13.41B while liabilities remain negligible at $5.98K. Technical indicators show oversold conditions with RSI at 26.02, though moving averages signal continued bearish pressure.
The outlook remains challenged by Federal Reserve policy uncertainty and rising Treasury yields pressuring precious metals. While oversold conditions may provide short-term bounce potential, the fundamental case lacks revenue generation. Investors face headwinds from dollar strength and hawkish Fed expectations, requiring careful risk management in this volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About iShares Silver Trust
The ETF seeks to reflect such performance before payment of the ETF's expenses and liabilities. It is not actively managed. The ETF does not engage in any activities designed to obtain a profit from, or to ameliorate losses caused by, changes in the price of silver.
Read more on SLV →
